Abstract:Objective: To establish and evaluate diagnostic efficacy and applicability of serum Golgi protein (GP) 73 based non-invasive diagnostic model with other conventional serological indicators for compensated stage hepatitis B cirrhosis. Methods: 666 cases with chronic hepatitis B (CHB) who had visited to the Fifth Medical Center of People's Liberation Army General Hospital from January 2010 to December 2017 were selected as the study subjects, and were classified according to compensated stage cirrhosis into clinical and pathological diagnosis group based on whether or not the liver histological examination was performed. A diagnostic model of compensated stage hepatitis B cirrhosis in the clinical diagnosis group was established. The current clinically used diagnostic model of liver cirrhosis, aspartate aminotransferase/platelet ratio index (APRI), fibrosis index (FIB)-4 and liver stiffness measurement (LSM) were compared. Eventually, the diagnostic model was verified step by step by pathological diagnosis group. Results: The area under the receiver operating characteristic curve (AUC) of GP73 and APRI, FIB-4, and LSM for cirrhosis patients in the clinical diagnosis group were 0.842, 0.857, 0.864, and 0.832, respectively. The diagnostic efficiency of the four indicators were of similar (P value > 0.05). A diagnostic model of compensated stage hepatitis B cirrhosis (GAPA) using logistic regression analysis was established: LogitP = 1/ [1 + exp (1.614-0.054 × GP73-0.045 × Age + 0.030 × PLT-0.015 × ALP)]. The AUC of the model was as high as 0.940 and the optimal cut-off value were 0.41. The corresponding diagnostic sensitivity and specificity were 0.92 and 0.82, respectively. The diagnostic efficiency was better than that of APRI, FIB-4, LSM and GP73 alone (P < 0.05). The AUC of GAPA was 0.877 in the pathological diagnosis group, which was similar to the diagnostic efficacy of LSM (0.891) and FIB-4 (0.847) (P > 0.1), but still superior to that of APRI (0.811) and GP73 alone (0.780) (P < 0.001). Conclusion: GAPA, a diagnostic model for compensated stage hepatitis B cirrhosis established in this study, has a good diagnostic efficacy in both the clinical and pathological diagnosis group, and has certain auxiliary diagnostic value in the areas where resources are relatively scarce or where LSM has not been developed.

Novel serum biomarker of Golgi protein 73 for the diagnosis of clinically significant portal hypertension in patients with compensated cirrhosis

The Diagnostic Potential of Golgi Protein 73 for Cirrhosis in Patients with Chronic Hepatitis C

Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries

Serum Gp73 is Also a Biomarker for Diagnosing Cirrhosis in Population with Chronic HBV Infection.

Golgi Protein 73(GP73), a Useful Serum Marker in Liver Diseases

[Clinical application of serum Golgi protein 73 in patients with chronic liver diseases].

[Detection and Evaluation of Serum GP73, a Resident Golgi Glycoprotein, As a Marker in Diagnosis of Hepatocellular Carcinoma].

Diagnostic value of Golgi protein 73 alone and in combination with alpha fetoprotein in hepatocellular carcinoma

Expression of GP73 in Liver Cirrhosis and Its Assistant Value in Grading of Liver Cirrhosis

Value of serum Golgi protein 73 in assisting the diagnosis of moderate or severe liver injury in patients with chronic hepatitis B

Serum GP73 for Diagnosing Decompensated Cirrhosis in Population with Chronic HBV Infections

Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis

Diagnostic and prognostic validity of Golgi protein 73 in hepatocellular carcinoma

Advances on Golgi Glycoprotein 73 and Its Association with Diseases

[Establishment and Preliminary Application of Serum Golgi Protein 73 Based Noninvasive Diagnostic Model for Compensated Stage Hepatitis B Cirrhosis].

Serum Golgi protein 73 as a tumor marker in diagnosis of primary hepatic cancer

Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta- analysis

Relationship between N-glycosylated protein gp73 and Child-Pugh stage in cirrhotic patients

Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma.

Whether the Golgi protein 73 could be a diagnostic serological marker in hepatocellular carcinoma: a meta analysis

Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis.